Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 214
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Weekly Psychedelic Policy Briefing: October 5, 2026
Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
Psychedelic Churches Need Psychedelic Seminaries
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy...
MindMed Enrolls First Participant in a Study of its Session Monitoring...
PT285 – Andrew Penn, NP – The Need for Nurses in...
Psychedelic Research Bulletin: December 2021
Nova Mentis Provides Corporate Update – 2022 Planned Catalysts
Filament Health and Cybin Therapeutics Announce Licensing Agreement
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule...
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...
PharmaDrug Announces Resignation of Director
Load more